Since our results showed that in vivo zymosan treatment significantly enhanced IL15 production by splenic macrophages (Figure 1), zymosan might prevent AD development by upregulating IFNγ-producing KLRG1+ NK cells, which will be explored in future studies. The gene discussed is KLRG1; the disease is Alzheimer disease.